Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd D Armstrong

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Oncoimmunology|January 18, 2021
Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigenZoila A Lopez-Bujanda, Matthew G Chaimowitz, Todd D Armstrong, et al.
International Journal of Cancer|September 22, 2010
CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor responseDung T Le, Brian H Ladle, Timothy Lee, et al.
Trends in Molecular Medicine|March 14, 2026
Recent developments in cancer immuno-interception strategiesZirui Zhu, Jocelyn Mathew, Benjamin Barrett, et al.
JCI Insight|September 4, 2020
Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine developmentNeeha Zaidi, Mariya Soban, Fangluo Chen, et al.
Plos One|February 24, 2012
Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsVivian L Weiss, Timothy H Lee, Hong Song, et al.
Plos One|November 1, 2019
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunityMark Yarchoan, Aditya A Mohan, Lauren Dennison, et al.
International Immunopharmacology|March 11, 2017
Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivoMelek M E Sunay, Jeremy B Foote, James M Leatherman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanismElizabeth A Manning, John G M Ullman, James M Leatherman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 16, 2020
Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma DevelopmentNina J Chu, Robert A Anders, Elana J Fertig, et al.
JCI Insight|May 22, 2020
Effects of B cell-activating factor on tumor immunityMark Yarchoan, Won Jin Ho, Aditya Mohan, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Oncoimmunology|January 18, 2021
Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigenZoila A Lopez-Bujanda, Matthew G Chaimowitz, Todd D Armstrong, et al.
International Journal of Cancer|September 22, 2010
CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor responseDung T Le, Brian H Ladle, Timothy Lee, et al.
Trends in Molecular Medicine|March 14, 2026
Recent developments in cancer immuno-interception strategiesZirui Zhu, Jocelyn Mathew, Benjamin Barrett, et al.
JCI Insight|September 4, 2020
Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine developmentNeeha Zaidi, Mariya Soban, Fangluo Chen, et al.
Plos One|February 24, 2012
Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsVivian L Weiss, Timothy H Lee, Hong Song, et al.
Plos One|November 1, 2019
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunityMark Yarchoan, Aditya A Mohan, Lauren Dennison, et al.
International Immunopharmacology|March 11, 2017
Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivoMelek M E Sunay, Jeremy B Foote, James M Leatherman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanismElizabeth A Manning, John G M Ullman, James M Leatherman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 16, 2020
Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma DevelopmentNina J Chu, Robert A Anders, Elana J Fertig, et al.
JCI Insight|May 22, 2020
Effects of B cell-activating factor on tumor immunityMark Yarchoan, Won Jin Ho, Aditya Mohan, et al.
Pageof 5